Skip to main content
Clinical Trials/NCT01462188
NCT01462188
Unknown
Phase 4

Immediate Versus Delayed Stenting in Patients With ST-Elevation Myocardial Infarction Undergoing Mechanical Intervention

Marco Valgimigli1 site in 1 country100 target enrollmentOctober 2011

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Myocardial Infarction
Sponsor
Marco Valgimigli
Enrollment
100
Locations
1
Primary Endpoint
Myocardial blush grade (MBG) equal or greater than 2
Last Updated
14 years ago

Overview

Brief Summary

The goal of primary PCI is to restore anterograde myocardial flow. Stenting a largely thrombotic lesion may determine distal embolisation of thrombotic material therefore deteriorating myocardial perfusion.

Detailed Description

In the setting of largely thrombotic lesions such as those treated in the context of primary PCI, stenting often results in distal micro and macro-embolisation which hampers coronary flow and microvascular recovery. Interestingly in some of these studies comparing BMS versus balloon angioplasty an early hazard associated to the use of stent has been reported. Thus, investigators hypothesize in this protocol that refraining from stenting during the acute phase of ST segment myocardial infarction is safe and associated to improved myocardial recovery as compared to acute stenting.

Registry
clinicaltrials.gov
Start Date
October 2011
End Date
October 2015
Last Updated
14 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor Investigator
Principal Investigator

Marco Valgimigli

Head of the Catheterization laboratory

Università degli Studi di Ferrara

Eligibility Criteria

Inclusion Criteria

  • chest pain for \>30 min with ST-segment elevation of one mm or more in 2 or more contiguous ECG leads or with presumably new left bundle-branch block
  • admission either within 12 h of symptom onset or between 12 and 24 h with evidence of continuing ischaemia

Exclusion Criteria

  • the exclusion criteria will include history of bleeding diathesis or documented allergy/intolerance or contraindication to clopidogrel or ticlopidine or prasugrel
  • inability to assume an oral P2Y12 receptor blocker on a consecutive daily basis for a minimum of 6 months, or to heparin or aspirin
  • uncontrolled hypertension (systolic or diastolic arterial pressure \>180 mmHg or 120, respectively, despite medical therapy)
  • limited life expectancy, e.g. neoplasms, others
  • inability to obtain informed consent
  • pregnancy
  • patients were not enrolled if they were clinically unstable, presented with severe arrhythmia, or had known contraindications to CMR (claustrophobia, pacemakers, or implantable defibrillator devices)

Outcomes

Primary Outcomes

Myocardial blush grade (MBG) equal or greater than 2

Time Frame: post-procedure

The MBG will be estimated visually by 2 experienced observers, as previously described.

Secondary Outcomes

  • ST segment elevation resolution(30 minutes after the procedure)
  • ST segment elevation Resolution(90 minutes after the procedure)
  • infarct size(5 days)
  • Infarct size(6 months)
  • microvascular obstruction(6 months)
  • Mortality(6 months)

Study Sites (1)

Loading locations...

Similar Trials